Lake Street Sticks to Their Buy Rating for Immunome (IMNM)
Lake Street's Chad Messer maintains a Buy rating for Immunome (IMNM) with a $22 price target. Messer, who covers the Healthcare sector, has an average return of -0.7% and a 37.91% success rate. Immunome also received a Buy rating from Stephens's Sudan Loganathan, while TR reiterated a Hold rating on November 12.
In a report released today, Chad Messer from Lake Street maintained a Buy rating on Immunome, with a price target of $22.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Messer covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Oncolytics Biotech, and Genelux Corp.. According to TipRanks, Messer has an average return of -0.7% and a 37.91% success rate on recommended stocks.
In addition to Lake Street, Immunome also received a Buy from Stephens’s Sudan Loganathan in a report issued yesterday. However, on November 12, TR | OpenAI – 4o reiterated a Hold rating on Immunome (NASDAQ: IMNM).
